Biointron - Antibody Discovery, Antibody Production, Stable cell line, Protein Expression, CRO

Bispecific antibodies are rapidly transforming the therapeutic landscape, especially in oncology and autoimmune diseases. Such recombinant molecules can bind to two different antigens at the same time, offering greater specificity in targeting disease pathways. Since their introduction, the area of bispecifics has held tremendous promise in oncological cancers like multiple myeloma and lymphomas.

In vitro display technologies are a group of methods used to display diverse antibody libraries on the surface of solid supports or particles like phage, yeast, ribosomes, and bacteria. They are powerful tools for the discovery and engineering of novel antibodies with desired binding properties and were first explored for antibody selection over 30 years ago.

Chimeric antibodies, formed by combining the variable regions of one species with the constant domains of another, are essential for various research fields, especially in vivo and in vitro studies. These hybrid antibodies maintain their antigen-binding specificity while offering flexibility in different research settings. This flexibility makes them highly valuable for biotherapeutic research, immunoassays, and diagnostic applications.